Enrico Franceschi1, Antonella Mura1, Dario De Biase2, Giovanni Tallini3, Annalisa Pession2, Maria Pia Foschini4, Daniela Danieli5, Stefano Pizzolitto6, Elena Zunarelli7, Giovanni Lanza8, Daniela Bartolini9, Enrico Maria Silini10, Michela Visani3, Enrico Di Oto11, Alicia Tosoni1, Santino Minichillo1, Giuseppe Lamberti1, Andrea Lanese1, Alexandro Paccapelo1, Stefania Bartolini1, Alba A Brandes1. 1. Department of Medical Oncology, Bellaria-Maggiore Hospitals, Azienda USL, IRCCS Institute of Neurological Sciences, Bologna, Italy. 2. Department of Pharmacy and Biotechnology (FaBiT), Molecular Diagnostic Unit AUSL ofBologna, University of Bologna, Bologna, Italy. 3. Department of Medicine (Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale) - Molecular Diagnostic Unit, Azienda USL di Bologna, University of Bologna School of Medicine, Bologna, Italy. 4. Department of Biomedical & Neuro Motor Sciences, Anatomic Pathology 'M Malpighi' at Bellaria Hospital, University of Bologna, Bologna, Italy. 5. Department of Pathology, San Bortolo Hospital, Vicenza, Italy. 6. Department of Pathology, Santa Maria della Misericordia Hospital, Udine, Italy. 7. Department of Pathology, University Hospital, Modena, Italy. 8. Department of Pathology, S Anna University Hospital & University of Ferrara, Ferrara, Italy. 9. Department of Pathology, Bufalini Hospital, Cesena, Italy. 10. Department of Pathology, University Hospital of Parma, Via Gramsci 14, 43100, Parma, Italy. 11. Section of Anatomic Pathology, Department of Biomedical & Neuromotor Sciences, University of Bologna, 40139, Bologna, Italy.
Abstract
AIM: To evaluate relevance of clinical and molecular factors in adult low-grade gliomas (LGG) and to correlate with survival. METHODS: We reviewed records from adult LGG patients from 1991 to 2015 who received surgery and had sufficient tissue to molecular biomarkers characterization. RESULTS: 213 consecutive LGG patients were included: 17.4% were low-risk, according to Radiation Therapy Oncology Group (RTOG) risk assessment. IDH 1/2 mutation, 1p/19q co-deletion, MGMT methylation were found in 93, 50.8 and 65.3% of patients. Median follow-up was 98.3 months. In univariate analysis, overall survival was influenced by extent of resection (p = 0.011), IDH mutation (p < 0.001), 1p/19q co-deletion (p = 0.015) and MGMT methylation (p = 0.013). In multivariate analysis, RTOG clinical risk (p = 0.006), IDH mutation (p < 0.001) and 1p/19q co-deletion (p = 0.035) correlated with overall survival. RTOG clinical risk (p = 0.006), IDH mutation (p < 0.001) and 1p/19q co-deletion (p = 0.035) correlated with overall survival. CONCLUSION: Both clinical and molecular factors are essential to determine prognosis and treatment strategies.
AIM: To evaluate relevance of clinical and molecular factors in adult low-grade gliomas (LGG) and to correlate with survival. METHODS: We reviewed records from adult LGG patients from 1991 to 2015 who received surgery and had sufficient tissue to molecular biomarkers characterization. RESULTS: 213 consecutive LGG patients were included: 17.4% were low-risk, according to Radiation Therapy Oncology Group (RTOG) risk assessment. IDH 1/2 mutation, 1p/19q co-deletion, MGMT methylation were found in 93, 50.8 and 65.3% of patients. Median follow-up was 98.3 months. In univariate analysis, overall survival was influenced by extent of resection (p = 0.011), IDH mutation (p < 0.001), 1p/19q co-deletion (p = 0.015) and MGMT methylation (p = 0.013). In multivariate analysis, RTOG clinical risk (p = 0.006), IDH mutation (p < 0.001) and 1p/19q co-deletion (p = 0.035) correlated with overall survival. RTOG clinical risk (p = 0.006), IDH mutation (p < 0.001) and 1p/19q co-deletion (p = 0.035) correlated with overall survival. CONCLUSION: Both clinical and molecular factors are essential to determine prognosis and treatment strategies.
Authors: Enrico Franceschi; Alicia Tosoni; Dario De Biase; Giuseppe Lamberti; Daniela Danieli; Stefano Pizzolitto; Elena Zunarelli; Michela Visani; Enrico Di Oto; Antonella Mura; Santino Minichillo; Chiara Scafati; Sofia Asioli; Alexandro Paccapelo; Stefania Bartolini; Alba A Brandes Journal: Oncologist Date: 2019-02-18
Authors: Lucas Alverne F Albuquerque; João Paulo Almeida; Leonardo José Monteiro de Macêdo Filho; Andrei F Joaquim; Hugues Duffau Journal: Neurosurg Rev Date: 2020-08-07 Impact factor: 3.042
Authors: Louise Carstam; Alba Corell; Anja Smits; Anna Dénes; Hanna Barchéus; Klara Modin; Helene Sjögren; Sandra Ferreyra Vega; Thomas Olsson Bontell; Helena Carén; Asgeir Store Jakola Journal: Front Oncol Date: 2022-01-10 Impact factor: 6.244
Authors: Keng Lam; Blaine S C Eldred; Bryan Kevan; Sean Pianka; Brittany A Eldred; Serendipity Zapanta Rinonos; William H Yong; Linda M Liau; Phioanh L Nghiemphu; Timothy F Cloughesy; Richard M Green; Albert Lai Journal: Neurooncol Adv Date: 2022-03-01
Authors: Georg Alexander Gihr; Diana Horvath-Rizea; Elena Hekeler; Oliver Ganslandt; Hans Henkes; Karl-Titus Hoffmann; Cordula Scherlach; Stefan Schob Journal: Front Oncol Date: 2020-02-25 Impact factor: 6.244